{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"16.5","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"description":"PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using Lugano Classification","dispersionType":"95% Confidence Interval","groups":[{"description":"Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent","id":"OG000","title":"Zanubrutinib"}],"paramType":"MEDIAN","populationDescription":"Efficacy analysis set consisted of all participants with a confirmed diagnosis of MZL who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years and 2.5 months","title":"Progression-free Survival (PFS) by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}